Long-term data on the course of the disease in resected early-stage NSCLC patients with EGFR and KRAS mutations are also limited, although these represent extremely important data in the context of the recently approved adjuvant anti-EGFR therapy in stage IB–IIIA NSCLC after radical resection cited above [6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.